
zzso zzso zzso levels correlate with disease outcomes in zzso cell zzso zzso zzso zzso a zzso zzso zzso against zzso was evaluated in a zzso phase zzso study in patients with progressive zzso zzso 

In part 1, 11 patients received 1, 3, 6, or zzso at weeks 1, 4 and zzso zzso 2 zzso in part 2, 37 patients randomly received 3 or 6 zzso zzso zzso 4; in part 3, 20 low-risk patients received zzso zzso zzso zzso zzso WHO response criteria were assessed at weeks 7, 11, the zzso zzso and when clinically zzso 

zzso was well tolerated overall, with no maximum tolerated dose or immune response zzso In all, 5 out of 11, 17 out of 37, and 9 out of 20 patients in parts 1, 2, and 3, respectively, received extended treatment beyond 4-6 initial zzso In part 2, stable disease zzso zzso or better was achieved by 11 out of 17 zzso 3 zzso treated patients (one partial response zzso zzso months, 10 zzso and 10 out of 20 zzso zzso treated patients (10 zzso In part 3, documented complete or zzso was not observed, but 13 out of 20 zzso patients achieved zzso 

zzso zzso disease in zzso of progressive zzso zzso zzso One zzso was zzso Given the zzso safety profile of zzso and poor correlation of zzso shrinkage with clinical benefit demonstrated for other zzso therapies, further evaluation of zzso strategies and/or combination therapy may be considered for patients with zzso 

